Targeted pill takes aim at rare cancer mutations
NCT ID NCT06303167
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the drug can shrink tumors or slow the cancer's spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib (a kinase inhibitor pill)
- What this could lead to
- If successful, this could provide a treatment option for patients with various cancers that have certain EGFR mutations, potentially shrinking tumors or delaying progression.
- What could go wrong
- This is a small, early-phase trial with only 19 participants, so results may not apply broadly. The drug may not work for all mutation types, and side effects like lung inflammation or heart problems are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a new PET tracer reveal hidden immune clues in tumors?
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?